a. Efficacy: Clinical (surrogate parameters): PSA-kinetics, histology; patient-relevant outcomes: 5-year survival, disease-free survival, overall survival, quality of life<br>b. Safety: Morbidity: acute/ chronic urinary dysfunction, urinary incontinence, strictures/ stenosis (bladder neck, ureter), erectile dysfunction, recto-urethral fistula, chronic pain, mortality (p. 13)

localized prostate cancer

C61